Waiting to inhale: noninjectable insulin, are we there yet?
Subcutaneous injection has been the only route of insulin administration for patients with type 1 or type 2 diabetes for the past 80 years. Although research and development in this time has improved the insulin treatments themselves, it is only now that alternative routes of insulin administration are becoming viable. Many avenues of insulin administration have been explored, including oral, buccal, and pulmonary routes. However, these methods of noninvasive insulin delivery are not free from difficulties and only preliminary data are available for oral insulin pills and buccal insulin sprays. The most promising alternative route of delivery appears to be inhaled insulin and two devices are already in phase III testing. Nevertheless, inhaled insulin devices will still have to overcome some problems and recent studies show that these challenges are currently being confronted. It appears that years of research into noninvasive methods of insulin administration are close to fruition and this review outlines the most recent findings in this area.
Hermansen
Kjeld
K
Aarhus University Hospital, Department of Endocrinology & Metabolism, Tage-Hansens gade 2, Aarhus DK-8000, Denmark. Kjeld.Hermansen@aas.auh.dk.
D000280:Administration, Inhalation; D000284:Administration, Oral; D000818:Animals; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D004195:Disease Models, Animal; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D007328:Insulin / Q000008:administration & dosage* / Q000627:therapeutic use
D007004:Hypoglycemic Agents; D007328:Insulin